

DEPARTMENTS OF LABOR, HEALTH AND HUMAN SERVICES,
AND EDUCATION, AND RELATED AGENCIES AP-
PROPRIATIONS BILL, 2016

, 2015.—Committed to the Committee of the Whole House on the State of the
Union and ordered to be printed

Mr. COLE, from the Committee on Appropriations,
submitted the following

R E P O R T

[To accompany H.R.]

The Committee on Appropriations submits the following report in explanation of the accompanying bill making appropriations for the Departments of Labor, Health and Human Services (except the Food and Drug Administration, the Agency for Toxic Substances and Disease Registry and the Indian Health Service), Education, Committee for Purchase from People Who Are Blind or Severely Disabled, Corporation for National and Community Service, Corporation for Public Broadcasting, Federal Mediation and Conciliation Service, Federal Mine Safety and Health Review Commission, Institute of Museum and Library Services, Medicare Payment Advisory Commission, National Council on Disability, National Labor Relations Board, National Mediation Board, Occupational Safety and Health Review Commission, Railroad Retirement Board, and the Social Security Administration for the fiscal year ending September 30, 2016, and for other purposes.

INDEX TO BILL AND REPORT

		<i>Page number</i>	
		<i>Bill</i>	<i>Report</i>
Summary of Estimates and Appropriation		3	3
General Summary of the Bill			3
Title I—Department of Labor:			
Employment and Training Administration	2		6
Employee Benefits Security Administration	15		14
Pension Benefit Guaranty Corporation	15		14

liver cancer, as well as liver cancer program projects. The Committee encourages more focus on the development of biomarkers to serve as early detection markers of cancer to therefore offer the prospect of improved outcomes.

Melanoma.—The Committee encourages NCI to develop a 5-year plan across NCI's divisions, and coordinate with other federal agencies and advocates to align melanoma research resources. The Committee understands the NCI MATCH Trial and Exceptional Responders Initiative may provide valuable insight to benefit melanoma subpopulations knowledge and encourages use of these mechanisms. The Committee requests an update in the fiscal year 2017 budget request on these efforts.

NCI Designated Cancer Centers.—The Committee requests an update in the fiscal year 2017 request on how NCI supports or plans to support Institutional Development Award programs in states to broaden the NCI designated cancer center representation within these states.

NCI Precision Medicine Initiative (PMI).—The Committee provides the requested funds to support the five-year NCI PMI plan that will support activities such as the pediatric MATCH trial, clinical trials for five major cancer types based on genomic driven data, liquid biopsies, new models of cancer diagnostics, test targeted agents for clinical trials, and the related informatics infrastructure. The Committee understands the NCI PMI is a one-time increase of \$70,000,000 for five years. The Committee requests NCI to provide a breakout in the fiscal year 2017 budget request and future years with the specific science and funding details with these and NCI funds already supporting the PMI activity. The details should include long-term goals, milestones, and annual progress. The Committee encourages NCI, as scientifically feasible, to support existing research networks, especially collaborative efforts among NCI-supported cancer centers and institutions serving historically underserved populations as they have certain attributes of cancer genomic data sharing that may be particularly effective.

Office of Cancer Survivorship.—The Committee requests a report in the fiscal year 2017 budget request on actions planned or ongoing to focus resources and attention to the youngest of cancer survivors.

Pancreatic Cancer.—The Committee encourages NCI to prioritize support for meritorious research for pancreatic cancer generally and specifically related to early detection of pancreatic cancer. The Committee encourages a focus on promising research to test members of high-risk pancreatic cancer families, including non-invasive screening methods. The Committee requests an update in the fiscal year 2017 budget request on these efforts.

Pediatric Low Grade Astrocytoma Research (PLGA).—The Committee encourages continued research efforts toward the identification of new therapies for PLGA patients, to include clinical trials. The Committee urges NCI and NIH to seek public/private partnerships opportunities on PLGA research. The Committee requests an update in the fiscal year 2017 budget request on on-going and planned activities across NIH.